
New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
In a newly released report, MGA highlights the broad economic impact of Otsuka in the United States.
In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023.
In a new white paper, Alex Brill details the consequences of regulatory uncertainty for businesses and provides a close look at the ongoing uncertainty facing companies owned by ESOPs.